102. The palm is ~0.5% TBSA - Insurance companies denying coverage - Malignancy risk in JAK inhibitors - MACE risk in JAK inhibitors - Oral azoles for head-and-neck dermatitis

The palm is ~0.5% TBSA [article]Insurance companies denying coverage [article]Malignancy risk in JAK inhibitors [article]MACE risk in JAK inhibitors [article]Oral azoles for head-and-neck dermatitis [article]Luke's PDPC course and the Intermountain Derm Society meeting: https://registration.socio.events/e/idspdpc23/promo-codes/ATTENDEE Connect with us!- Web: https://dermaspherepodcast.com/- Twitter: @DermaspherePC- Instagram: dermaspherepodcast- Facebook: https://www.facebook.com/DermaspherePodcast/- Check out Luke and Michelle’s other podcast, SkinCast! https://healthcare.utah.edu/dermatology/skincast/Luke and Michelle report no significant conflicts of interest… BUT check out our friends at:- Kikoxp.com(a social platform for doctors to share knowledge)- https://www.levelex.com/games/top-derm (A free dermatology game to learn more dermatology!)